Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

The new National Cancer Plan launches with goal of cutting cancer death rate by half in 25 years

By Brian Buntz | April 3, 2023

National Cancer Plan

[Image courtesy of National Institutes of Health]

Today, the U.S. Department of Health and Human Services (HHS) debuted the National Cancer Plan with an ambitious albeit vague quest to “end cancer as we know it.”

Specifically, the initiative will serves as a guideline to support President Biden’s Cancer Moonshot objectives, which aims to reduce the cancer mortality rate by 50% over a 25-year period.

NCI will lead the National Cancer Plan and Cancer Moonshot program

HHS will put the National Institutes of Health’s (NIH) National Cancer Institute (NCI) in charge of the program, which supports the Cancer Moonshot initiative from President and First Lady Biden.

The President’s Cancer Moonshot has galvanized the goal of advancing the fight against cancer,” said Dr. Monica M. Bertagnolli, National Cancer Institute director, in a press release.

Despite Biden’s focus on ramping up oncology research and COVID-19 therapy development, much of the pharmaceutical industry has opposed President Biden’s efforts to reduce prescription drug pricing. Earlier this year, the trade organization PhRMA said the Biden-backed Inflation Reduction Act was already having a drag on R&D for drug development.

In any event, the U.S. cancer death has fallen significantly in recent decades. Since 1991, cancer deaths have fallen by about one-third as a result of advances in treatments, earlier cancer detection and declined tobacco use,

For pharmaceutical companies, the National Cancer Plan could increase funding and support for oncology research and development.

The initiative’s goal of eliminating inequities in cancer care, however, might lead to increased scrutiny of drug pricing and accessibility.

Historical context and the evolving focus on oncology research

The U.S. government has ramped up its focus on oncology since the 1970s. In 1971, Richard Nixon signed the National Cancer Act, kickstarting a war on cancer. “I hope in the years ahead we will look back on this action today as the most significant action taken during my Administration,” Nixon said in 1971. In his State of the Union address that same year, Nixon said, “The time has come in America when the same kind of concentrated effort that split the atom and took man to the moon should be turned toward conquering this dread disease”.

In particular, the National Cancer Act bolstered research efforts and boosted cancer research funding. The National Cancer Act also established the National Cancer Program, an initiative of the National Cancer Institute (NCI) under the NIH umbrella.

In 2016, then Vice-President Biden launched an original Cancer Moonshot initiative. Drawing inspiration from his son Beau who died a year earlier from brain cancer, Biden worked to accelerate accelerate cancer research, improve patient access to care, and foster collaboration among researchers.

The original Cancer Moonshot drew from a $1 billion investment proposed by Obama.


Filed Under: Drug Discovery, Oncology
Tagged With: Cancer Moonshot, cancer mortality, National Cancer Plan, NCI, oncology research, pharmaceutical industry
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE